Skip to main content

SHORT INFORMATIVE REVIEW ON SINGLE SHOT INSULIN FOR DIABETICS

 

Clinical courses

 

Clinical courses

About Author:
Vijay M. Waghulkar1* (M.Pharm, D.B.M.), Dr. Supriya S. Deshpande2 (M.Pharm, Ph.D), Pooja A. Kohle(M.Sc)
*Corresponding author
1. Lecturer, Dept of Quality Assurance
Vidyabharati, College of Pharmacy, Camp, Amravati – 444601,
Maharastra, India.

2.Professor and HOD
Punjabrao Memorial Medical College of Pharmacy,
Panchvati,  , Amravati – 444602,
Maharastra, India

3. Lecturer,Dept. Cosmectic Technology
Vidyabharati Mahavidyala, Camp, Amravati – 444601,
Maharastra, India.

Abstract
Diabetes mellitus is caused due to deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin producD.Diabetes mellitus often referred to as diabetes—is a condition in which the body either does not produce enough, or does not properly respond to, insulin, a hormoneproduced in the pancreas. Insulin enables cells to absorb glucose in order to turn it into energy. This causes glucose to accumulate in the blood, leading to various potential complications.

To overcome such complication Indian scientist have develop new techniques for diabetics i.e. single shot insulin which ,  is very essentials, blessful, create new ray of hope to the patients of diabetics ,give relief upto 120 days.

REFERENCE ID: PHARMATUTOR-ART-1145

Introduction
Diabetes mellitus is one of the main threats to human health in 21st century. It is one of the most common non communicable diseases globally and is fifth leading cause of death. With the rising trend in the prevalence of diabetes it is estimated that by the year 2025 the number of diabetic persons in India will be 57.2 millions. According to WHO report in India the annual cost of care was Rs. 2400.00 for patients treated with oral hypoglycemic agents to Rs. 12000.00 for patients taking insulin. Diabetes can affect nearly every organ in the body. It causes blindness, end stage renal diseases, lower extremity amputation, ischemic heart diseases, peripheral vascular diseases and neuropathy. It is a global problem and number of those affected is increasing day by day.

Diabetes mellitus is caused due to deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin producD.Diabetes mellitus often referred to as diabetes—is a condition in which the body either does not produce enough, or does not properly respond to, insulin, a hormoneproduced in the pancreas. Insulin enables cells to absorb glucose in order to turn it into energy. This causes glucose to accumulate in the blood, leading to various potential complications.

Many types of diabetes are recognized: The principal three are:

  • Type 1:Results from the body's failure to produce insulin. It is estimated that 5–10% of Americans who are diagnosed with diabetes have type 1 diabetes. Presently most persons with type 1 diabetes take insulin injections.
  • Type 2:Results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with absolute insulin deficiency. Most Americans who are diagnosed with diabetes have type 2 diabetes.
  • Gestational diabetes:Pregnant women who have never had diabetes before but who have high blood sugar (glucose) levels during pregnancy are said to have gestational diabetes. Gestational diabetes affects about 4% of all pregnant women. It may precede development of type 2 (or rarely type 1) DM.

Other forms of diabetes mellitus are categorized separately from these. Examples include congenital diabetes due to genetic defects of insulin secretion, cystic fibrosis-related diabetes, steroid diabetes induced by high doses of glucocorticoids, and several forms of monogenic diabetes.

A team of scientists of the National Immunology Institute of India,  have developed a fresh approach to insulin injection wherein 'Supramolecular Insulin Assembly-II (SIA-II)', a form of the hormone, is used for a sustained treatment of diabetes mellitus type-I,Such noval formulation which give its action from  60-120 days, which is consider as new ray of hope for diabetics.

SIA-II, which is in the form of a prodrug, when injected releases just above basal levels of insulin into the blood in a sustained manner, Surolia said. A prodrug is a chemical that undergoes changes in the body into a more active material.

This just above basal level of insulin is adequate to tackle the increase in blood glucose levels after meals and does not cause severe hypoglycemia, a low sugar condition, in the morning, a dreadful condition faced by diabetics.

SIA-II upon injection forms a depot at the site, from where insulin monomers are released which act on the body's cells to regulate uptake of glucose for months after a single injection.

The technique is being seen as one with tremendous therapeutic potential and constitutes a new way of treatment for diabetic patients.

02. MODE OF ACTION
SIA-IIupon injection forms a depot at the site, fromWhere insulin on monomers are released which act on  the body's cells to regulate uptake of glucose for Months after a single injection.

FIGURE 01-SINGLE SHOT INSULIN

03. ADVANTAGES
1. As compare to conventional dosage form its reduces dosages frequency.

2.Less needle phobias relief from the trauma of pricking oneself daily.

3.It also does not causes ever hypoglycemia  in the morning dreadful condition faced by diabetics.

4.The drug counters bad effects of diabetes such as It also does not cause severe hypoglycemia in the  Cataract and kidney failure.

NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.

SUBMIT YOUR ARTICLE/PROJECT AT articles@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email

FIND OUT MORE ARTICLES AT OUR DATABASE

04. FUTURE SCOPE
1.NII scientists have patented the technology and transferred itTo a US company which will conduct clinical trials on humans For toxicity.

2.It will take another 4-6 years for the insulin shot to reach themarket.

05. OUT COME
This techniques is very essentials, blessful, create new ray of hope to the patients of diabetics .

06. PRESENT SENERIO
1.SIA-II was successfully tested on rats which demonstratedLower blood glucose levels to normal values upto120days.

2.The research took three years ,at a cost over Rs.20 lakh andThe findings have already been licensed to an American company, which will test new form of insulin in humans.

REFERENCE
1.    Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. (November 2004). "Intranasal insulin improves memory in humans.". Psychoneuroendocrinology 29 (10): 1326–34. doi:10.1016/j.psyneuen.2004.04.003. PMID 15288712.
2.    Benedict C, Brede S, Schiöth HB, Lehnert H, Schultes B, Born J, Hallschmid M. (2010). "Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men.". Diabetes 60 (1): 114–118. doi:10.2337/db10-0329. PMC 3012162. PMID 20876713.
3.    "Entrez Gene: INS insulin". www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3630.
4.    Bell GI, Pictet RL, Rutter WJ, Cordell B, Tischer E, Goodman HM (March 1980). "Sequence of the human insulin gene". Nature 284 (5751): 26–32. doi:10.1038/284026a0. PMID 6243748.
5.    Melloul D, Marshak S, Cerasi E (2002). "Regulation of insulin gene transcription". Diabetologia 45 (3): 309–26. doi:10.1007/s00125-001-0728-y. PMID 11914736.
6.    Jang WG, Kim EJ, Park KG, Park YB, Choi HS, Kim HJ, Kim YD, Kim KS, Lee KU, Lee IK (2007). "Glucocorticoid receptor mediated repression of human insulin gene expression is regulated by PGC-1alpha". Biochem. Biophys. Res. Commun. 352 (3): 716–21. doi:10.1016/j.bbrc.2006.11.074. PMID 17150186.
7.    Sanger F, Tuppy H (September 1951). "The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates". Biochem. J. 49 (4): 463–81. PMC 1197535. PMID 14886310. ; Sanger F, Tuppy H (September 1951). "The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates". Biochem. J. 49 (4): 481–90. PMC 1197536. PMID 14886311. ; Sanger F, Thompson EO (February 1953). "The amino-acid sequence in the glycyl chain of insulin. I. The identification of lower peptides from partial hydrolysates". Biochem. J. 53 (3): 353–66. PMC 1198157. PMID 13032078. ; Sanger F, Thompson EO (February 1953). "The amino-acid sequence in the glycyl chain of insulin. II. The investigation of peptides from enzymic hydrolysates". Biochem. J. 53 (3): 366–74. PMC 1198158. PMID 13032079.
8.    Katsoyannis PG, Fukuda K, Tometsko A, Suzuki K, Tilak M, Panayotis G.; Fukuda, Kouhei; Tometsko, Andrew; Suzuki, Kenji; Tilak, Manohar (1964). "Insulin Peptides. X. The Synthesis of the B-Chain of Insulin and Its Combination with Natural or Synthetis A-Chin to Generate Insulin Activity". Journal of the American Chemical Society 86 (5): 930–932. doi:10.1021/ja01059a043.
9.    Kung YT, Du YC, Huang WT, Chen CC, Ke LT (November 1965). "Total synthesis of crystalline bovine insulin". Sci. Sin. 14 (11): 1710–6. PMID 5881570.
10.   Marglin B, Merrifield RB (1966). "The Synthesis of Bovine Insulin by the Solid Phase Method". Journal of the American Chemical Society 88 (21): 5051–5052. doi:10.1021/ja00973a068. PMID 5978833.
11.   Dunn MF (August 2005). "Zinc-ligand interactions modulate assembly and stability of the insulin hexamer -- a review". Biometals 18 (4): 295–303. doi:10.1007/s10534-005-3685-y. PMID 16158220.
12.   Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D (November 2009). "Molecular basis for insulin fibril assembly". Proc. Natl. Acad. Sci. U.S.A. 106 (45): 18990–5. doi:10.1073/pnas.0910080106. PMC 2776439. PMID 19864624.
13.   Steiner DF, Oyer PE (February 1967). "The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma". Proc. Natl. Acad. Sci. U.S.A. 57 (2): 473–480. doi:10.1073/pnas.57.2.473. PMC 335530. PMID 16591494.
14.   Gustin N (2005-03-07). "Researchers discover link between insulin and Alzheimer's". EurekAlert!. American Association for the Advancement of Science. eurekalert.org/pub_releases/2005-03/l-rdl030205.php. Retrieved 2009-01-01.
15.   de la Monte SM, Wands JR (February 2005). "Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease". J. Alzheimers Dis. 7 (1): 45–61. PMID 15750214. iospress.metapress.com/openurl.asp?genre=article&issn=1387-2877&volume=7&issue=1&spage=45.
16.   Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (February 2005). "Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?". J. Alzheimers Dis. 7 (1): 63–80. PMID 15750215. iospress.metapress.com/openurl.asp?genre=article&issn=1387-2877&volume=7&issue=1&spage=63.
17.   Hellman B, Gylfe E, Grapengiesser E, Dansk H, Salehi A (2007). "[Insulin oscillations--clinically important rhythm. Antidiabetics should increase the pulsative component of the insulin release]" (in Swedish). Lakartidningen 104 (32–33): 2236–9. PMID 17822201.
18.   A Dictionary of Units of MeasurementBy Russ Rowlett, the University of North Carolina at Chapel Hill. June 13, 2001
19.   Iwase, H.; Kobayashi, M.; Nakajima, M.; Takatori, T. (2001). "The ratio of insulin to C-peptide can be used to make a forensic diagnosis of exogenous insulin overdosage". Forensic science international 115 (1–2): 123–127. doi:10.1016/S0379-0738(00)00298-X. PMID 11056282.  edit
20.   Xianjun Fang, Shuang Xing Yu, Yiling Lu, Robert C. Bast, Jr. James R. Woodgett, and Gordon B. Mills (2000). "Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A". Proceedings of the National Academy of Sciences of the United States of America 97 (22): 11960–11965. doi:10.1073/pnas.220413597. PMC 17277. PMID 11035810.
21.   Edward J McManus, Kei Sakamoto, Laura J Armit, Leah Ronaldson, Natalia Shpiro, Rodolfo Marquez and Dario R Alessi (2005). "Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis". The EMBO Journal 24 (8): 1571–1583. doi:10.1038/sj.emboj.7600633. PMC 1142569. PMID 15791206.
22.   Painter PC, Mosher LE, Rhoads C (July 1982). "Low-frequency modes in the Raman spectra of proteins". Biopolymers 21 (7): 1469–72. doi:10.1002/bip.360210715. PMID 7115900.
23.   Chou KC (December 1983). "Identification of low-frequency modes in protein molecules". Biochem. J. 215 (3): 465–9. PMC 1152424. PMID 6362659.
24.   Chou KC (May 1988). "Low-frequency collective motion in biomacromolecules and its biological functions". Biophys. Chem. 30 (1): 3–48. PMID 3046672.
25.   Bergamini E, Cavallini G, Donati A, Gori Z (October 2007). "The role of autophagy in aging: its essential part in the anti-aging mechanism of caloric restriction". Ann. N. Y. Acad. Sci. 1114: 69–78. doi:10.1196/annals.1396.020. PMID 17934054.
26.   Benziane B, Chibalin AV (2008). "Frontiers: skeletal muscle sodium pump regulation: a translocation paradigm". American Journal of Physiology. Endocrinology and Metabolism 295 (3): E553-8. doi:10.1152/ajpendo.90261.2008. PMID 18430962. ajpendo.physiology.org/content/295/3/E553.long.
27.   Clausen T (2008). "Regulatory role of translocation of Na+-K+ pumps in skeletal muscle: hypothesis or reality?". American Journal of Physiology. Endocrinology and Metabolism 295 (3): E727-8. doi:10.1152/ajpendo.90494.2008. PMID 18775888. ajpendo.physiology.org/content/295/3/E727.long.
28.   Gupta AK, Clark RV, Kirchner KA (1992). "Effects of insulin on renal sodium excretion". Hypertension 19 (1 Suppl): 178-182. PMID 1730458.
29.   William C. Duckworth, Robert G. Bennett and Frederick G. Hamel (1998). "Insulin Degradation: Progress and Potential". Endocrine Reviews 19 (5): 608–624. doi:10.1210/er.19.5.608. PMID 9793760. edrv.endojournals.org/cgi/content/full/19/5/608#F1.
30.   Palmer, BF et. al. 2010. "Carbohydrate and insulin metabolism in chronic kidney disease." UpToDate Online, accessed Nov. 13, 2010.
31.   From SemBiosys, A New Kind Of InsulinINSIDE WALL STREET By Gene G. Marcial(AUGUST 13, 2007)
32.   i-sis.org.uk/gmSaffloweHumanPro-Insulin.php
33.   NDTV Profit December 11, 2009-Biocon May Launch Oral Insulin
34.   The American Institute of Nutrition (1967). "Proceedings of the Thirty-first Annual Meeting of the American Institute of Nutrition"(PDF). Journal of Nutrition 92: 509. jn.nutrition.org/cgi/reprint/92/4/507.pdf.
35.   Paulesco, N.C. (1921, August 31), "Recherche sur le rôle du pancréas dans l'assimilation nutritive.", Archives Internationales de Physiologie 17: 85-103
36.   Lestradet, H. (1997), "Le 75e anniversaire de la découverte de l’insuline.", Diabetes & Metabolism 23 (1): 112, em-consulte.com/en/article/79613
37.   Banting FG, Best CH. (1922), "The internal secretion of pancreas.", J Lab Clin Med 7: 251-266, biology.buffalo.edu/courses/bio130/medler/banting.pdf
38.   Ian Murray (1971). "Paulesco and the Isolation of Insulin"(PDF). Journal of the History of Medicine and Allied Sciences 26 (2): 150–157. PMID 4930788. jhmas.oxfordjournals.org/cgi/reprint/XXVI/2/150.pdf.
39.   Wright JR (December 2002). "Almost famous: E. Clark Noble, the common thread in the discovery of insulin and vinblastine". CMAJ 167 (12): 1391–6. PMC 137361. PMID 12473641.
40.   Krishnamurthy, Kalayya (2002). Pioneers in scientific discoveries. Mittal Publications. p. 266. ISBN 9788170998440. books.google.com/books?id=dAXYzzDL_9oC&pg=PA266. Retrieved 26 July 2011.
41.   Abigail Zuger (October 4, 2010). "Rediscovering the First Miracle Drug". New York Times. nytimes.com/2010/10/05/health/05insulin.html?_r=1&hp=&pagewanted=all. Retrieved 2010-10-06. "Elizabeth Hughes was a cheerful, pretty little girl, five feet tall, with straight brown hair and a consuming interest in birds. On Dr. Allen’s diet her weight fell to 65 pounds, then 52 pounds, and then, after an episode of diarrhea that almost killed her in the spring of 1922, 45 pounds. By then she had survived three years, far longer than expected. And then her mother heard the news: Insulin had finally been isolated in Canada."
42.   Marcotte, Bob (November 22, 2010). "Rochester's John Williams a man of scientific talents". Democrat and Chronicle. Gannett Company(Rochester, New York): pp. 1B, 4B. Archived from the originalon November 22, 2010. webcitation.org/5uRSurOlI. Retrieved November 22, 2010.

NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.

SUBMIT YOUR ARTICLE/PROJECT AT articles@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email

FIND OUT MORE ARTICLES AT OUR DATABASE